Zusammenfassung
Der Hypogonadismus des Mannes basiert auf einer unzureichenden Gonadenfunktion. Die damit verbundene Verminderung an endogener Testosteronproduktion kann erworben oder angeboren sein. Dieser Testosteronmangel führt zu typischen klinischen Veränderungen, die erste Hinweise für eine Testosteronersatztherapie geben. Weniger als 10% der Patienten mit einem Hypogonadismus erhalten jedoch eine adäquate Behandlung. Zur Therapie eines Hypogonadismus mit Testosteron stehen in Deutschland gegenwärtig verschiedene Präparate und Applikationsformen zur Verfügung. Intramuskuläre, perorale, transdermale, sublinguale und subkutane Präparate zeigen Unterschiede in Pharmakodynamik, Pharmakokinetik, Preis und Anwenderfreundlichkeit und sind daher individuell anzuwenden. Regelmäßige klinische und laborchemische Kontrollen von Wirkung, Nebenwirkungen und Kontraindikationen sind notwendig.
Abstract
Male hypogonadism is based on an insufficient gonadal function, especially testosterone deficiency. The decreased endogenous production of testosterone can be acquired or congenital. The lack of testosterone results in typical clinical symptoms which give initial indications for testosterone replacement therapy. Nevertheless, less than 10% of the affected patients receive an adequate treatment. Presently different preparations and application forms are available for the therapy of hypogonadism with testosterone. Intramuscular, peroral, transdermal, sublingual and subcutaneous preparations show differences in pharmacodynamics, pharmacokinetics, price and handling. Therefore these formulations should be applied individually. Regular clinical and chemical controls of effect, side effects and contraindications are essential along with long-term substitution.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Nieschlag E, Swerdloff R, Behre HM et al (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 28(3):125–127
Behre HM, Nieschlag E (1998) Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM (eds) Testosterone – Action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 329–348
Behre HM, Abshagen K, Oettel M et al (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I-studies. Eur J Endocrinol 140:414–419
Nieschlag E, Büchter D, Eckardstein S von et al (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin Endocrinol (Oxf) 51:757–763
Wang C, Nieschlag E, Swerdloff R et al (2009) ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 21(1):1–8
Handelsman DJ (1998) Clinical pharmacology of testosterone pellet implants. In: Nieschlag E, Behre HM (eds) Testosterone – action, deficiency, substitution, 2nd edn. Springer, Berlin Heidelberg New York, pp 348–364
Jockenhövel F, Vogel E, Kreutzer M et al (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 45:61–71
Kelleher S, Turner L, Howe C et al (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol (Oxf) 51:469–471
Gooren LJG (1998) A ten year safety study on the oral androgen testosterone undecanoate. J Androl 15:212–215
Kohn FM, Schill WB (2003) A new oral testosterone undecanoate formulation. World J Urol 21:311–315
Korbonits M, Kipnes M, Grossman AB (2004) Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism. Int J Clin Pract 58:1073–1080
Wang C, Berman N, Longstreth JA et al (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men:application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 85:964–969
Mazer N, Fisher D, Fischer J et al (2005) Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J Sex Med 2:227–234
Alberti I, Grenier A, Kraus H, Carrara DN (2005) Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2:935–950
Chik Z, Johnston A, Tucker AT et al (2006) Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol 61:275–279
Nieschlag E, Behre HM (2000) Therapie mit Testosteron. In: Nieschlag E, Behre HM (Hrsg) Andrologie – Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, 2. Aufl. Springer, Berlin Heidelberg New York, S 349–366
Curran MJ, Bihrle W 3rd (1999) Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53:423–424
Behre HM, Kliesch S, Leifke E et al (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390
Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ (1976) Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7(3):138–145
Eckardstein S von, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23(3):419–425
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Popken, G. Testosteronsubstitution. Urologe 49, 37–42 (2010). https://doi.org/10.1007/s00120-009-2196-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-009-2196-9